title: [Treatment of mild and moderate hypertension with enalapril (multicenter study of enap and enap N in Ukraine)].
abstract: OBJECTIVE
  Assessment of efficiency and safety of enalapril (enap) and its combination with hydrochlorotiaside (enap-N).
  
  
  METHODS
  127 patients with mild and moderate blood hypertension entered an open non-comparative multicenter trial. 60 of them received enap (group 1), 67--enap N (group 2). Group 1 patients were given enap for 2 weeks in a dose 10 mg/day. If this dose was not adequate to normalize blood pressure, it was raised to 20-40 mg/day. Patients of group 2 received enap-N one tablet a day for 3 weeks. If the pressure persisted higher than 140/90 mm Hg, the treatment was continued for 3 weeks more in a dose of 2 tablets a day.
  
  
  RESULTS
  Blood pressure lowered under 140/90 mm Hg in 40 patients of group 1 (66.7%). Systolic pressure dropped by 10 mm Hg minimum and diastolic by 5 mm minimum in 18 group 1 patients (30%). Enap-N reduced blood pressure under 140-90 mm Hg in 44 of 67 patients (65.7%). Systolic and diastolic pressure dropped, respectively, in 23(34.3%) patients.
  
  
  CONCLUSIONS
  Enap and enap-N tablets were found highly effective and well tolerated. Side effects were caused by lowering of blood pressure.
authors: G V
authors: GV
authors: Dziak
authors: S N
authors: SN
authors: Kolomiets
authors: A I
authors: AI
authors: Minakov
authors: I M
authors: IM
authors: Fushteĭ
authors: O G
authors: OG
authors: Iavorskiĭ
authors: V F
authors: VF
authors: Bekker
authors: V N
authors: VN
authors: Vankhanen
authors: I V
authors: IV
authors: Davydova
authors: V I
authors: VI
authors: Zaĭtseva
authors: T V
authors: TV
authors: Kolesnik
authors: V V
authors: VV
authors: Kolomiets
authors: E P
authors: EP
authors: Svishchenko
authors: A I
authors: AI
authors: Taran
authors: N A
authors: NA
authors: Shlykova
authors: B
authors: B
authors: Barbich-Zhagar
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D004232:Diuretics; D004359:Drug Therapy, Combination; D004656:Enalapril / Q000008:administration & dosage / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D006852:Hydrochlorothiazide / Q000008:administration & dosage / Q000627:therapeutic use; D006973:Hypertension / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D008875:Middle Aged; D012449:Safety; D012720:Severity of Illness Index; D049993:Sodium Chloride Symporter Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D004232:Diuretics; D049993:Sodium Chloride Symporter Inhibitors; D006852:Hydrochlorothiazide; D004656:Enalapril